Optical News

GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical...

DULUTH, Ga.--(BUSINESS WIRE)--National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that the Company is scheduled to present at the 2026 ICR Conference on Tuesday, January 13, 2026, at 9:00 a.m. Eastern Time. A live webcast of the presentation can be accessed in the “Investors” section of the Company’s website at ir.nationalvision.com. The webcast will be archived and available on the website shortly after the event. About National Vision Holdings, In...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, announced that based on preliminary estimates by STAAR’s proxy solicitor, STAAR did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held today. STAAR intends to terminate its merger agreement with Alcon. No terminat...

TAMPA, Fla.--(BUSINESS WIRE)--Lions World Vision Institute (LWVI) broke ground on its new $16 million Vision Health Center in Tampa’s historic Ybor City....

BARCELONA--(BUSINESS WIRE)--SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced the appointment of Don Munoz as Chief Financial Officer. Mr. Munoz, who is based in Boston, is a seasoned biotechnology finance leader with deep experience in financial strategy, operations and corporate development, complemented by a strong background in healthcare investment banking. “As we advance our lead progra...

NORWICH, England & CHICAGO--(BUSINESS WIRE)--Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used in combination with Ikarovec’s gene therapy candidate IKAR-003 for intermediate age-related macular degeneration (AMD). Following successful further evaluation of the t...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundation (GRF) during Glaucoma Awareness Month in January. Bausch + Lomb will also sponsor The Glaucoma Foundation’s (TGF) social media campaign to raise awareness of the disease and its impact by highlighting a glaucoma patient or advocate every day i...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously announced credit agreement refinancing. In connection with the closing, Bausch + Lomb has entered into a fourth amendment (the “Fourth Amendment”) to its existing credit agreement providing for a $2,802,125,000 tranche (the “Replacement Term Loans”...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe....

DUBLIN--(BUSINESS WIRE)--The "Diabetic Macular Edema (DME): Epidemiology Forecast to 2034" report has been added to ResearchAndMarkets.com's offering. In the 7MM, the diagnosed prevalent cases of DME in diabetes are expected to increase from 2,888,125 cases in 2024 to 3,463,149 cases in 2034, at an annual growth rate (AGR) of 1.99%. In 2034, the US will have the highest number of diagnosed prevalent cases of DME in diabetes in the 7MM, with 1,012,428 cases, whereas Japan will have the fewest di...